Company intelligence / Profile preview

DermAegis

Rockford, Illinois, USA

Ownership: Private
Development stage: Other

Overview

DermAegis is a biotechnology company specializing in advanced dermatological treatments and innovative drug delivery systems. The company leverages its proprietary liposomal and nanoparticle platforms to develop high-efficacy topical therapies, including its flagship LipoDEET insect repellent and a preclinical CRISPR-loaded nanoparticle spray for onychomycosis. DermAegis also operates in the bioactive wound care sector, providing tissue-engineered products and matrices for chronic and acute wound management. Headquartered in Rockford, Illinois, the company focuses on addressing unmet needs in skin health through precision delivery and regenerative medicine.

Therapeutic areas: OtherDermatologyInfectious Diseases
Modalities: LiposomesNanoparticleCRISPR-based therapyDevice
Industry: Biotech

Beyond the preview

Go deeper on DermAegis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DermAegis.

Explore the full profile